International business negotiations news: Roche and Merck reveal new partnership
Roche and Merck will work together to develop new treatments and diagnostics for hepatitis C.
Pharmaceuticals giants Roche and Merck have concluded
international business negotiations which will see them work
together on a new joint venture on treatments and diagnostics for
The move will see researchers from both firms collaborating to
examine combinations of investigational and marketed drugs to boost
the availability of new drugs for patients with the disease.
As part of the agreement, Roche will promote Victrelis to
doctors as part of a triple combination therapy strategy and the
two organisations will work together to better educate physicians
and patients on the diagnosis and treatment of hepatitis C.
Adam Schechter, executive vice-president and president, Global
Human Health, Merck, said such an alliance is in the best interests
of both firms.
"These agreements are consistent with both companies' goal of
improving healthcare outcomes for patients with chronic hepatitis
C," he added.
International business negotiations involving GlaxoSmithKline,
AstraZeneca and the University of Manchester saw an agreement
reached to build the Manchester Collaborative Centre for
Inflammation Research to advance research on inflammatory diseases
and develop remedies to tackle them.